Q-omics provides the consensus-scored RFPL4B profile across patient tissues and cancer cell-line models. RFPL4B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, RFPL4B is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, RFPL4B RNA expression shows 11,154 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, KICH, and TGCT as cancer lineages where RFPL4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RFPL4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RFPL4B survival associations across molecular data types. RFPL4B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RFPL4B RNA expression–survival associations across cancer types. High RFPL4B expression shows unfavorable associations in SCLC, KIRP, LUAD, COAD and STAD, but favorable associations in LGG. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify SCLC as the clearest survival context for RFPL4B RNA expression.
This table summarizes RFPL4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RFPL4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RFPL4B shows lower tumor expression in KICH, KIRC and KIRP and higher tumor expression in LIHC, PRAD and LUAD. The KICH box plot shows higher RFPL4B RNA expression in normal versus tumor tissue (log2 FC = −0.460, t-test p < 0.001).
This table shows molecular features associated with RFPL4B in patient tissues and cancer cell lines. In patient samples, RFPL4B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RFPL4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and KIDNEY.
